PLX NYSE Biological Products, (No Diagnostic Substances) Financials FY2016βFY2025
Protalix BioTherapeutics, Inc. had $52.7M of revenue in fiscal 2025, down 1.2% on the year before. Over five years, revenue changed β3.5% a year on average.
Last close Β· Oct 23, 2026
$2.55
0.8%Hi! I read Protalix BioTherapeutics, Inc.βs latest annual report (fiscal 2025). Here is what stands out:
Good So-so Weak
Are sales growing?
β1.2%
No. Sales fell 1.2% last year.
Does it make a profit?
β12.5%
No. It lost money last year.
Does profit turn into cash?
β25.8%
No. It spent more cash than it brought in.
How healthy are the accounts?
2 / 8
Weak. It passes 2 of 8 health tests.
How is the share priced?
10.6x
One share costs 10.6 times its yearly profit per share.
Rules of thumb on reported numbers. A starting point, not a recommendation.
Is it selling more, and how much does it keep?
In plain words: Every quarter, companies publish how much they sold and earned. These are the days Protalix BioTherapeutics, Inc. did it, and the next one. Share prices often move a lot on those days.
Next results
November 12, 2026
Thursday Β· in 17 days
| Date | Results for | Time | Source |
|---|---|---|---|
| Aug 12, 2026 | Q2 '26 | Before the market opens | 8-K β |
| May 13, 2026 | Q1 '26 | Before the market opens | 8-K β |
| Mar 18, 2026 | Q4 '25 | Before the market opens | 8-K β |
| Nov 13, 2025 | Q3 '25 | Before the market opens | 8-K β |
| Aug 14, 2025 | Q2 '25 | Before the market opens | 8-K β |
| May 9, 2025 | Q1 '25 | Before the market opens | 8-K β |
| Mar 17, 2025 | Q4 '24 | Before the market opens | 8-K β |
| Nov 14, 2024 | Q3 '24 | Before the market opens | 8-K β |
From SEC filings: the results press release (8-K) or, without one, the quarterly or annual report.
KIRA Β· Protalix BioTherapeutics, Inc. had $52.7M of revenue in fiscal 2025, down 1.2% on the year before. Over five years, revenue changed β3.5% a year on average. Its operating margin was β10.4%, down 17.8Β pts: of every 100 in sales, about β10 is left after running the business.
In plain words: Revenue is all the money customers paid. The margins show how many cents of each dollar of sales are left over at each step: after making the product (gross), after running the business (operating) and after everything, tax included (net).
Revenue
Revenue
Margins, % of revenue
Margins, % of revenue
KIRA Β· Protalix BioTherapeutics, Inc. lost $6.6M in fiscal 2025.
Loss periods are shown in red.
In plain words: Net income is the profit left after every cost and tax. Earnings per share (EPS) splits that profit across every share, so it shows what one share earned.
Net income
Net income
Diluted EPS
Diluted EPS
How much cash comes in, and where does it go?
KIRA Β· Free cash flow was β$13.6M in fiscal 2025, β25.8% of revenue.
Cash from operations minus capital spending.
In plain words: Profit on paper is not the same as cash in the bank. Free cash flow is the cash left after paying to run and maintain the business: the money it can hand back to shareholders, save or invest.
Free cash flow
Free cash flow
Cash from operations vs capital spending
Cash from operations vs capital spending
In plain words: Companies hand cash back in two ways: dividends (cash paid to shareholders) and buybacks (buying back their own shares, so each remaining share owns a bigger slice).
Dividends and buybacks
Diluted shares outstanding (annual)
KIRA Β· No open-market insider trades in the last 12 months.
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. βPlanβ marks trades under a pre-arranged Rule 10b5-1 plan.
In plain words: Insiders are the people who run or own a big part of the company. Buying with their own money can signal confidence; selling often has personal reasons, like taxes or diversifying.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
β
$0.0M
No open-market insider trades in the last 12 months.
Can it carry its debts, and how well does it use its money?
Cash, debt and the ratios that show how comfortably Protalix BioTherapeutics, Inc. can carry it.
In plain words: What the company owns and what it owes. More cash than debt is a cushion for bad times; a lot of debt leaves less room when business slows down.
Cash vs debt (incl. leases)
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $39.0M | $17.1M | $23.6M | $19.8M | $14.7M |
| Current ratio | 1.9x | 1.4x | 1.5x | 2.3x | 2.5x |
| Quick ratio | 1.3x | 0.9x | 1.1x | 1.5x | 1.5x |
| Total assets | $73.7M | $55.8M | $84.4M | $73.4M | $82.3M |
| Total liabilities | $79.7M | $66.4M | $50.9M | $30.2M | $34.1M |
| Shareholders' equity | β$6.0M | β$10.6M | $33.6M | $43.2M | $48.2M |
| Net debt (β = net cash) | β | β | β | β | β |
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
In plain words: How much profit the business makes on the money put into it. A higher percentage means each dollar invested works harder.
Return on capital, equity and assets (annual)
KIRA Β· Protalix BioTherapeutics, Inc. passes 2 of 8 financial health tests (Piotroski F-score).
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
In plain words: Nine yes/no tests of financial health, one point each. A green tick is a pass: 7 to 9 points is solid, 0 to 3 is weak.
| Test | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net income is positive | β | β | β | β | β | β | β | β | β | β |
| Cash from operations is positive | β | β | β | β | β | β | β | β | β | β |
| Return on assets rose | β | β | β | β | β | β | β | β | β | β |
| Cash from operations exceeds net income | β | β | β | β | β | β | β | β | β | β |
| Debt fell relative to assets | β | β | β | β | β | β | β | β | β | β |
| Current ratio rose | β | β | β | β | β | β | β | β | β | β |
| Share count didn't rise | β | β | β | β | β | β | β | β | β | β |
| Gross margin rose | β | β | β | β | β | β | β | β | β | β |
| Revenue rose relative to assets | β | β | β | β | β | β | β | β | β | β |
| F-score | β / 3 | 5 / 8 | 4 / 8 | 3 / 8 | 2 / 8 | 2 / 8 | 3 / 8 | 4 / 8 | 5 / 8 | 2 / 8 |
| Accruals ratio | 3.3% | β95.1% | β28.1% | 2.0% | 34.6% | β24.4% | 15.6% | 13.7% | β7.3% | 6.9% |
| Altman Z'' | β10.80 | β13.26 | β16.85 | β27.81 | β19.67 | β16.00 | β23.05 | β11.31 | β11.86 | β11.01 |
Every number, year by year.
Amounts in USD. Hover a ratioβs name for its definition.
In plain words: Every number we have, year by year. Download it as a spreadsheet if you want to dig deeper.
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $9.2M | $21.1M | $34.2M | $54.7M | $62.9M | $38.4M | $47.6M | $65.5M | $53.4M | $52.7M |
| Gross profit | $0.8M | $4.0M | $24.9M | $43.8M | $52.0M | $22.0M | $28.0M | $42.5M | $29.1M | $25.8M |
| Research and development | $30.4M | $32.2M | $33.3M | $44.6M | $38.2M | $29.7M | $29.3M | $17.1M | $13.0M | $19.6M |
| Operating income | β$33.2M | β$34.5M | β$19.3M | β$10.7M | $2.7M | β$20.5M | β$13.0M | $10.5M | $3.9M | β$5.5M |
| Pretax income | β | β | β | β | β$6.5M | β$27.6M | β$14.4M | $8.6M | $4.2M | β$5.6M |
| Income tax | β | β | β | β | β | β | $0.5M | $0.3M | $1.2M | $1.0M |
| Net income | β$29.4M | β$83.4M | β$26.5M | β$18.3M | β$6.5M | β$27.6M | β$14.9M | $8.3M | $2.9M | β$6.6M |
| Diluted EPS | β$0.29 | β$6.37 | β$1.80 | β$1.23 | β$0.22 | β$0.62 | β$0.31 | $0.09 | $0.04 | β$0.08 |
| Diluted shares | 0.10B | 0.01B | 0.01B | 0.01B | 0.03B | 0.04B | 0.05B | 0.08B | 0.08B | 0.08B |
| Cash flow | ||||||||||
| Cash from operations | β$32.1M | β$10.0M | β$7.7M | β$19.4M | β$26.1M | β$10.3M | β$25.0M | β$1.3M | $8.7M | β$12.0M |
| Capital expenditure | $0.8M | $1.0M | $0.7M | $0.6M | $0.7M | $1.5M | $0.6M | $1.1M | $1.3M | $1.6M |
| Free cash flow | β$32.9M | β$11.0M | β$8.4M | β$20.0M | β$26.8M | β$11.7M | β$25.6M | β$2.5M | $7.4M | β$13.6M |
| Depreciation and amortization | $2.0M | $1.9M | $1.7M | $1.6M | $1.3M | $1.1M | $1.1M | $1.2M | $1.3M | $1.5M |
| Stock-based compensation | $1.0M | $0.3M | $0.5M | $0.8M | $3.1M | $2.4M | $2.1M | $3.4M | $3.3M | $2.3M |
| Balance sheet | ||||||||||
| Cash and short-term investments | $63.3M | $51.2M | $37.8M | $17.8M | $18.3M | $39.0M | $17.1M | $23.6M | $19.8M | $14.7M |
| Current assets | $71.9M | $62.7M | $53.0M | $32.5M | $55.7M | $61.7M | $44.9M | $69.9M | $60.1M | $66.7M |
| Current liabilities | $66.2M | $22.8M | $25.4M | $40.2M | $86.5M | $33.2M | $32.4M | $45.5M | $25.6M | $26.5M |
| Inventory | $5.2M | $7.8M | $8.6M | $8.2M | $13.1M | $18.0M | $16.8M | $19.0M | $21.2M | $25.7M |
| Property and equipment, net | $8.7M | $7.7M | $6.4M | $5.3M | $4.8M | $5.0M | $4.6M | $5.0M | $4.6M | $4.9M |
| Total assets | $82.2M | $72.2M | $61.1M | $45.4M | $67.9M | $73.7M | $55.8M | $84.4M | $73.4M | $82.3M |
| Total liabilities | $92.2M | $102M | $114M | $116M | $95.0M | $79.7M | $66.4M | $50.9M | $30.2M | $34.1M |
| Shareholders' equity | β$10.0M | β$29.5M | β$52.9M | β$70.3M | β$27.0M | β$6.0M | β$10.6M | $33.6M | $43.2M | $48.2M |
| Margins | ||||||||||
| Gross margin | 8.7% | 19.0% | 72.8% | 80.1% | 82.7% | 57.4% | 58.9% | 64.9% | 54.5% | 48.8% |
| Operating margin | β360.5% | β163.8% | β56.4% | β19.6% | 4.3% | β53.4% | β27.3% | 16.0% | 7.3% | β10.4% |
| EBITDA margin | β338.9% | β154.6% | β51.5% | β16.6% | 6.4% | β50.4% | β25.0% | 17.8% | 9.8% | β7.7% |
| Net margin | β319.2% | β395.9% | β77.3% | β33.4% | β10.4% | β71.9% | β31.3% | 12.7% | 5.5% | β12.5% |
| FCF margin | β358.2% | β52.0% | β24.6% | β36.5% | β42.5% | β30.6% | β53.8% | β3.8% | 13.8% | β25.8% |
| Returns | ||||||||||
| Return on capital employed | β206.8% | β69.8% | β54.0% | β205.4% | β14.6% | β50.5% | β55.7% | 26.9% | 8.2% | β9.9% |
| Return on equity | β | β | β | β | β | β | β | 72.5% | 7.6% | β14.4% |
| Return on assets | β35.7% | β108.0% | β39.7% | β34.3% | β11.5% | β39.0% | β23.1% | 11.9% | 3.7% | β8.5% |
| Return on tangible equity | β | β | β | β | β | β | β | 24.8% | 6.8% | β13.7% |
| Growth | ||||||||||
| Revenue growth | β | 129.1% | 62.4% | 59.7% | 15.0% | β39.0% | 24.2% | 37.5% | β18.5% | β1.2% |
| Net income growth | β | β | β | β | β | β | β | β | β64.7% | β325.2% |
| EPS growth | β | β | β | β | β | β | β | β | β55.6% | β300.0% |
| FCF growth | β | β | β | β | β | β | β | β | β | β284.4% |
| Share count change | β | β87.1% | 12.2% | 0.8% | 96.4% | 51.4% | 9.8% | 70.0% | β1.7% | β3.1% |
| Financial health | ||||||||||
| Current ratio | 1.1x | 2.8x | 2.1x | 0.8x | 0.6x | 1.9x | 1.4x | 1.5x | 2.3x | 2.5x |
| Quick ratio | 1.0x | 2.4x | 1.8x | 0.6x | 0.5x | 1.3x | 0.9x | 1.1x | 1.5x | 1.5x |
| Capital allocation | ||||||||||
| Capex / revenue | 9.2% | 4.6% | 2.0% | 1.1% | 1.0% | 3.8% | 1.3% | 1.8% | 2.4% | 3.1% |
| Stock comp / revenue | 10.7% | 1.6% | 1.5% | 1.5% | 5.0% | 6.2% | 4.4% | 5.3% | 6.1% | 4.4% |
| Quality scores | ||||||||||
| Piotroski F-score | β | 5.0 | 4.0 | 3.0 | 2.0 | 2.0 | 3.0 | 4.0 | 5.0 | 2.0 |
| Altman Z'' | β10.8 | β13.3 | β16.8 | β27.8 | β19.7 | β16.0 | β23.1 | β11.3 | β11.9 | β11.0 |
| Accruals ratio | 3.3% | β95.1% | β28.1% | 2.0% | 34.6% | β24.4% | 15.6% | 13.7% | β7.3% | 6.9% |
Source: SEC EDGAR XBRL filings (CIK 0001006281). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.
